Sales of Intravenous Iron Drugs Market is Estimated to hit US$ 6.3 Bn at a CAGR of 8.5% by year 2032-end | Future Market Insights, Inc.

Future Market Insights Global and Consulting Pvt. Ltd.
Future Market Insights Global and Consulting Pvt. Ltd.

Ferric Carboxymaltose to Generate nearly 50% of the Intravenous Iron Drugs Market throughout the Analysis Period. The US market for Intravenous Iron Drugs is projected to expand at a CAGR of around 9.3% during 2022 – 2032.

DUBAI, United Arab Emirates, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Global Intravenous Iron Drugs Market was valued at US$ 2.6 Bn in 2021 and is expected to reach US$ 6.3 Bn by 2032, finds Fact.MR in a recent market survey. As per the findings of the report, Intravenous Iron Drugs revenue through Ferric Carboxymaltose will garner significant demand in the market as the bulk of revenue will be generated through them.

The American Heart Association predicts that by 2035, more than 130 million adults in the United States will have cardiovascular disease. In addition, the Centers for Disease Control and Prevention reports that 0.6 million Americans die each year from heart disease. This information leads directly to the number of hospital admissions.

The Ferric Carboxymaltose (FCM) segment led the market for intravenous iron medicines in 2021, with nearly 50% revenue share due to its expanding use, improved performance, and lower cost. It is a parenteral iron medication devoid of dextran which is suggested for the quick and high-dose replacement of depleted iron reserves. This medicine is a stable compound with the benefit of not containing any extraneous ingredients and having a very low immunogenic potential; hence, it poses a very low risk of anaphylactic responses. FCM has a higher effectiveness in terms of boosting hemoglobin levels and has fewer side effects. The tremendous rise may also be attributed to the FDA approval of Injectates in North America as well as its approval outside of North America.

Request Sample @

The region's expanding senior population is a primary driver of industry development. According to US Census Bureau forecasts, the number of Americans aged 65 and older would rise from 52 million in 2018 to roughly 95 million by 2060. Furthermore, the overall percentage of people aged 65 and older is projected to increase from 16% to 23%.

It may be linked to the presence of a higher incidence of cancer, intestinal illnesses, and renal disease in the specific area. These conditions also are reinforcing its dominance. It has also contributed to the growth of women's health awareness and the awareness about celiac disease.

Competitive Landscape

Some of the key players in the global Intravenous Iron Drugs market include Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc., Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; and Shield Therapeutics Plc among others.

Request Customization @

Some of the recent developments in the Intravenous Iron Drugs Market are:

  • In April 2018, AMAG Pharmaceuticals got FDA clearance for a supplementary new drug application for ferumoxytol injection to cover all eligible people with iron-deficiency anaemia (IDA) who cannot tolerate or do not respond to oral iron.

  • In May 2019, Rockwell Medical, Inc. filed a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the Intravenous (I.V.) version of Triferic.

  • In September 2020, Daiichi Sankyo announced the formation of its wholly-owned subsidiary Daiichi Sankyo Vietnam Company Limited. This program was launched in order to strengthen the company's Asian business platform.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Intravenous Iron Drugs Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Product Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types), by Indication (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications), across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Market Segments Covered in Intravenous Iron Drugs Industry Analysis

By Product Type:

  • Iron Dextran

  • Iron Sucrose

  • Ferric Carboxymaltose

  • Other Product Types

By Indication:

  • Chronic Kidney Disease

  • Inflammatory Bowel Disease

  • Cancer

  • Other Applications

Use promo code ->> FMITODAY to get flat 20% discount

Table of Content

1. Executive Summary

  1.1. Global Market Outlook

  1.2. Summary of Statistics

  1.3. Key Market Characteristics & Attributes

  1.4. Analysis and Recommendations

2. Market Overview

  2.1. Market Coverage / Taxonomy

  2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

  3.1. Risk Assessment

      3.1.1. COVID-19 Crisis and Impact on Demand

      3.1.2. COVID-19 Impact Benchmark with Previous Crisis

      3.1.3. Impact on Market Value (US$ Mn)

      3.1.4. Assessment by Key Countries

      3.1.5. Assessment by Key Market Segments

      3.1.6. Action Points and Recommendation for Suppliers

  3.2. Key Trends Impacting the Market

  3.3. Formulation and Product Development Trends

Report Preview:

Explore FMI’s Extensive ongoing Coverage on Healthcare Domain:

Protective Mask Market Size : The market share for protective masks is estimated to rise from US$ 0.9 billion in 2019 to US$ 25.1 billion in 2022 before depreciating to US$ 3.0 billion by 2027.

Acute Kidney Injury Treatment Market Demand : The global Acute Kidney Injury Treatment Market is expected to witness staggering growth, registering 8.2% CAGR during the forecast period (2022-2029).

Bipolar Disorder Drugs and Treatment Market Trends : The global bipolar disorder drugs and treatment market is forecasted to grow at a moderate CAGR of 3%, reaching nearly US$ 8.1 Bn by 2032 from US$ 5.7 Bn in 2021.

Bacteriophage Market Analysis : The global demand for bacteriophage market is expected to witness significant growth at 4.2% CAGR from 2021 to 2031, topping a valuation of US$ 41.46 Mn in 2021.

Over-The-Counter (OTC) Veterinary Drugs Market Forecast : The overall sales of over-the-counter (OTC) veterinary drugs are projected to expand at a CAGR of 8.1% over the forecast period (2022-2032) and reach US$ 18.14 Bn by the end of 2032.

About Us :
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us: 
Future Market Insights, Inc.
1602-6 Jumeirah Bay X2 Tower, 
Plot No: JLT-PH2-X2A, 
Jumeirah Lakes Towers, Dubai, 
United Arab Emirates 
For Sales Enquiries: